Does Risperdal Reduce Irritability in Autism?
Risperdal (risperidone) is FDA-approved for treating irritability associated with autistic disorder in children and adolescents aged 5-16, including aggression, deliberate self-injury, and temper tantrums.[1] Two pivotal 8-week, double-blind, placebo-controlled trials (n=101 and n=98) showed significant reductions in irritability scores on the Aberrant Behavior Checklist-Irritability subscale (ABC-I), with effect sizes of 0.9 and 1.4. Doses of 0.5-1.17 mg/day were most effective, outperforming placebo by 57% and 69% in responder rates (≥25% ABC-I improvement).[2][3]
Open-label extensions up to 6 months confirmed sustained benefits, with 69% of patients maintaining response at low doses (≤1.17 mg/day).[4]
How Does Risperdal Compare to Other Treatments?
Risperdal outperforms placebo in short-term trials but edges out aripiprazole (Abilify, also FDA-approved for this use) slightly in meta-analyses, with similar ABC-I reductions (-12.4 vs. -11.2 points) but faster onset.[5] Neither beats behavioral therapies long-term; aripiprazole has less weight gain risk.[6] No head-to-head trials exist with non-antipsychotics like risperidone vs. guanfacine or SSRIs.
| Drug | FDA-Approved for Autism Irritability? | ABC-I Reduction (vs. Placebo) | Common Dose Range |
|------|--------------------------------------|-------------------------------|-------------------|
| Risperdal (risperidone) | Yes (ages 5-16) | -14 to -18 points | 0.5-2.5 mg/day |
| Abilify (aripiprazole) | Yes (ages 6-17) | -8 to -12 points | 5-15 mg/day |
| Seroquel (quetiapine) | No | -9 points (limited data) | Off-label |
What Do Long-Term Studies Show?
Benefits wane after 1-2 years without adjunct therapy; a 24-week trial found 64% relapse upon discontinuation vs. 33% on continued risperidone.[7] Real-world data from over 1,000 patients indicate 50-70% response rates, but only 30-40% sustain gains beyond 6 months due to tolerance or side effects.[8]
What Side Effects Should Parents Watch For?
Weight gain averages 4-5 kg in 6 months (vs. 1 kg placebo), with 20-30% developing hyperprolactinemia (elevated milk hormone, risking gynecomastia or menstrual issues).[2][3] Other risks: sedation (40%), EPS (14%), metabolic changes (18% BMI increase). Long-term: 1-2% tardive dyskinesia risk. Monitoring includes baseline labs, weight, and prolactin levels every 3-6 months.[9] FDA black box warns of increased mortality in elderly dementia patients (not autism), but pediatric data show no excess deaths.[1]
Who Makes Risperdal and When Do Patents Expire?
Janssen (Johnson & Johnson) developed Risperdal; generics entered in 2008 after key patents expired (original 1993 approval).[10] DrugPatentWatch.com lists no active pediatric exclusivity; multiple generics (e.g., from Teva, Mylan) cost $10-50/month vs. $500+ brand.
Can Doctors Prescribe It Off-Label for Adults?
Yes, but evidence is weaker; small adult autism trials show modest ABC-I drops (-9 points), limited by sample size (n<50).[11] Guidelines (AACAP) recommend only for ages 5-17 with severe symptoms unresponsive to behavioral interventions first.[12]
[1]: FDA Label, Risperidone (Risperdal), 2023.
[2]: RUPP Autism Network, NEJM 2002;347:1343-51.
[3]: McCracken et al., NEJM 2002;347:1351-7.
[4]: RUPP Follow-up, J Am Acad Child Adolesc Psychiatry 2005;44:72-80.
[5]: Meta-analysis, Pediatrics 2012;129:e1341-52.
[6]: Correll et al., JAMA 2009;302:1027-38.
[7]: NEJM 2009;361:440-9.
[8]: Autism Speaks database, 2022 review.
[9]: AACAP Practice Parameters, J Am Acad Child Adolesc Psychiatry 2013;52:779-90.
[10]: DrugPatentWatch.com, Risperdal patents.
[11]: McDougle et al., Am J Psychiatry 2008;165:1392-9.
[12]: NICE Guidelines, Autism Spectrum Disorder, 2013 (updated 2021).